Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Chief Financial Officer
On June 15, 2020, Vaseem Mahboob, Chief Financial Officer of Endologix, Inc.
(the "Company"), delivered his resignation to the Company, effective July 1,
2020, in order to pursue other opportunities.
Appointment of Interim Chief Financial Officer and Principal Accounting Officer
On June 18, 2020, the Board of Directors of the Company (the "Board") appointed
Cindy Pinto, the Company's current Vice President, Financial Planning and
Analysis, as interim Chief Financial Officer and principal financial officer of
the Company, and Tim Brady, the Company's current Controller, as Corporate
Secretary and the Company's principal accounting officer, each to be effective
upon Mr. Mahboob's resignation on July 1, 2020.
Ms. Pinto, age 52, has served as the Company's Vice President, Financial
Planning and Analysis, since October 2018. Prior to that, Ms. Pinto served as
the Company's Senior Finance Director from February 2016 through September 2018
and as Finance Director from September 2014 through January 2016. Prior to
joining the Company, Ms. Pinto served as Finance Director at Covidien. Ms. Pinto
received a BS in Accounting from Villanova University and an MBA from New York
University.
Mr. Brady, age 39, has served as the Company's Controller since July 2015. Prior
to that, Mr. Brady served as the Company's Assistant Controller from September
2013 until July 2015 and as Manager, Corporate Accounting and Financial
Reporting from May 2012 until September 2013. Prior to joining the Company, Mr.
Brady served as Financial Reporting Manager at Alliance Healthcare Services,
Inc. Mr. Brady is a Certified Public Accountant (active). Mr. Brady received a
BA in Business Administration with Accounting Emphasis from California State
University, Fullerton.
There is no arrangement or understanding pursuant to which either Ms. Pinto or
Mr. Brady were appointed to their respective positions, and there are no related
party transactions between the Company and Ms. Pinto or Mr. Brady reportable
under Item 404(a) of Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ENDOLOGIX, INC. 
